Oppenheimer & CO Inc Vbi Vaccines Inc Transaction History

Oppenheimer & CO Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$0.29 - $0.64 $5,104 - $11,264	-17,600 Reduced 28.81%	43,500 $13,000
Q4 2022 Feb 07, 2023	SELL	$0.38 - $22.5 $13,376 - $792,000	-35,200 Reduced 36.55%	61,100 $23,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $23.4 $1,095 - $35,100	-1,500 Reduced 1.53%	96,300 $68,000
Q2 2022 Aug 08, 2022	SELL	$0.66 - $1.81 $1,716 - $4,706	-2,600 Reduced 2.59%	97,800 $80,000
Q1 2022 May 12, 2022	BUY	$1.27 - $2.47 $35,433 - $68,913	27,900 Added 38.48%	100,400 $166,000
Q4 2021 Feb 02, 2022	BUY	$2.21 - $3.22 $3,476 - $5,065	1,573 Added 2.22%	72,500 $170,000
Q3 2021 Nov 12, 2021	SELL	$2.8 - $3.72 $11,200 - $14,880	-4,000 Reduced 5.34%	70,927 $220,000
Q2 2021 Aug 03, 2021	SELL	$2.61 - $4.17 $27,274 - $43,576	-10,450 Reduced 12.24%	74,927 $251,000
Q1 2021 May 10, 2021	BUY	$2.91 - $4.32 $18,507 - $27,475	6,360 Added 8.05%	85,377 $265,000
Q4 2020 Feb 11, 2021	BUY	$2.15 - $3.5 $2,171 - $3,535	1,010 Added 1.29%	79,017 $217,000
Q3 2020 Nov 13, 2020	BUY	$2.77 - $6.17 $108,603 - $241,907	39,207 Added 101.05%	78,007 $223,000
Q2 2020 Aug 11, 2020	BUY	$0.87 - $3.13 $10,962 - $39,438	12,600 Added 48.09%	38,800 $120,000
Q1 2020 May 08, 2020	BUY	$0.73 - $1.91 $7,519 - $19,673	10,300 Added 64.78%	26,200 $25,000
Q4 2019 Feb 07, 2020	BUY	$0.48 - $1.38 $7,632 - $21,942	15,900 New	15,900 $22,000

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.